[Research progress of pyruvate kinase type M2 in hepatocellular carcinoma].
Zhonghua Gan Zang Bing Za Zhi
; 30(1): 117-120, 2022 Jan 20.
Article
in Zh
| MEDLINE
| ID: mdl-35152683
ABSTRACT
Primary hepatocellular carcinoma is one of the most common high-grade malignant tumors in the world. Its incidence ranks fifth among malignant tumors in China, and various therapeutic measures have poor curative effect. Pyruvate kinase type M2 is a key enzyme in the glycolytic pathway, and its abnormal expression in liver cancer is closely related to the proliferation, metastasis, diagnosis, treatment, prognosis, as well as drug and radiation resistance. Therefore, multi-pathway targeted regulation of pyruvate kinase type M2 use is expected to become a new direction for the treatment of primary liver cancer.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Country/Region as subject:
Asia
Language:
Zh
Journal:
Zhonghua Gan Zang Bing Za Zhi
Journal subject:
GASTROENTEROLOGIA
Year:
2022
Type:
Article
Affiliation country:
China